International Archives of Allergy and Immunology最新文献

{"title":"Prognostic Relevance of MDK and TIMP1 with Immune Infiltration in Lung Adenocarcinoma.","authors":"Qinghua Zhu, Qingqing Huang, Xiaohua He, Miaomiao Jiang, Junkai Fu, Chenyuan Ding","doi":"10.1159/000547102","DOIUrl":"10.1159/000547102","url":null,"abstract":"<p><strong>Introduction: </strong>Lung adenocarcinoma (LUAD) is a common and fatal form of lung cancer, with varying expressions of midkine (MDK) and tissue inhibitor of metalloproteinase (TIMP1) across different cancers. However, their specific roles in LUAD progression and tumor immunity remain unclear.</p><p><strong>Methods: </strong>We analyzed RNA-seq data from TCGA using the ggpubr R package to compare MDK and TIMP1 expression in normal versus LUAD tissues. This was validated through qRT-PCR and Western blot. LUAD patients were categorized into high and low expression groups for MDK and TIMP1, and their impacts on overall survival (OS), disease-free interval (DFI), progression-free interval (PFI), and disease-specific survival (DSS) were assessed using Kaplan-Meier curves and receiver operation characteristic curves. Kyoto Encyclopedia of Genes and Genomes and Gene Ontology enrichment analyses were performed for 50 genes similar to MDK and TIMP1, and a gene-gene interaction network was created with GeneMANIA, examining differentially expressed genes across both expression groups. We also evaluated the mutational landscape and immune cell infiltration correlations. Finally, the relationship between MDK, TIMP1 and immune cells was explored by immunohistochemical (IHC) experiments.</p><p><strong>Results: </strong>MDK and TIMP1 were significantly overexpressed in LUAD. Patients with low MDK and TIMP1 expressions had better OS, DFI, DSS, and PFI. The AUC values for MDK and TIMP1 were 0.943 and 0.875, respectively, with TIMP1 identified as a risk factor for OS. Genes similar to MDK were enriched in the Proteasome pathway, while those akin to TIMP1 were linked to endopeptidase activity. No survival impact was noted from mutations in these genes. Higher expression of MDK and TIMP1 correlated with reduced tumor purity and altered immune scores, suggesting increased immune dysfunction in the high TIMP1 group. IHC results showed that when MDK and TIMP1 expression levels were higher, B cell and TREG cell infiltration was stronger, but macrophage infiltration was weaker.</p><p><strong>Conclusion: </strong>MDK and TIMP1 significantly influence the prognosis and progression of LUAD and immune cell infiltration, highlighting their potential as targets for immunotherapy.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-19"},"PeriodicalIF":1.8,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144730290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between allergic rhinitis and oral disease: a meta-analysis.","authors":"Xuelian Yi, Zili Wen, Wei Deng, Danyan Mao, Qingsong Huang","doi":"10.1159/000547503","DOIUrl":"https://doi.org/10.1159/000547503","url":null,"abstract":"<p><strong>Introduction: </strong>The bidirectional relationship between allergic rhinitis (AR) and oral disease remains controversial. Therefore, this study aimed to amalgamate the current body of scientific literature to summarize and elucidate the association between AR and oral disease.</p><p><strong>Methods: </strong>A comprehensive search of PubMed, Embase, Cochrane Library, and Web of Science identified observational studies exploring AR and oral diseases. The study results, complete with their respective 95% confidence intervals (CIs), were aggregated by employing a random-effects model for data synthesis. Supplementary subgroup and sensitivity analyses were conducted to evaluate the stability and reliability of the study outcomes.</p><p><strong>Results: </strong>Nine studies were included. When examining oral health status as the exposure, the pooled results showed no significant associated with the odds of AR (OR=1.01, 95%CI:0.84-1.22, p=0.884; I²=95%). Similarly, when evaluating AR as the exposure, no overall association was observed between AR and the odds of oral diseases (OR=0.97, 95%CI:0.76-1.23, p=0.798; I²=100%). However, in subgroup analyses limited to cross-sectional studies examining the association between AR and oral diseases, a reduced odds was observed (OR=0.77, 95%CI:0.67-0.89, p<0.001; I²=0%), suggesting a possible inverse correlation in these specific study designs.</p><p><strong>Conclusion: </strong>This meta-analysis found no significant overall association between oral health and allergic rhinitis in either direction of exposure. Considerable heterogeneity was present among studies, particularly in analyses of AR as an exposure. Subgroup findings from cross-sectional studies suggest a potential inverse relationship between allergic rhinitis and oral diseases; however, these results should be interpreted cautiously due to study design limitations and require validation in future prospective studies.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-13"},"PeriodicalIF":1.8,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144730289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Naturally Composed and Size-Excluded Hymenoptera Venom Preparations on the Safety and Efficacy of Venom Immunotherapy: A Monocentric Experience.","authors":"Jörg Fischer, Lena Löffelad, Paula Kranert, Manfred Kneilling, Sebastian Volc","doi":"10.1159/000547194","DOIUrl":"10.1159/000547194","url":null,"abstract":"<p><strong>Introduction: </strong>The first-line treatment for patients with Hymenoptera venom allergy, a potentially life-threatening condition, is venom immunotherapy (VIT). However, for reasons still unclear, honeybee VIT (HBV-IT) is less effective than yellow jacket VIT (YJV-IT).</p><p><strong>Methods: </strong>This retrospective monocentric study aimed to investigate the safety and efficacy of naturally composed Hymenoptera venom (NC-HV) in a rush protocol involving a high total venom dose and to compare the results with those previously obtained using size-excluded Hymenoptera venom (SE-HV). Data regarding the number of build-up cycles and maintenance of VIT with NC-HV were retrieved from institutional records. The VIT protection rate was determined by the results of the sting challenge test (SCT).</p><p><strong>Results: </strong>We evaluated 648 individuals treated with NC-HV and compared their results with data from 1,258 individuals treated with SE-HV. The frequency of systemic reactions (SRs) with NC-HV in HBV-IT was 25.6%, and that with YJV-IT was 10.1%. Compared with previous experience with SE-HV, the use of NC-HV was associated with an increased frequency of SRs (SR rates of HBV-IT 10.4 and YJV-IT 6.3%). The protection rate in HBV-IT, as determined by SCT, was 100% with NC-HV, which is notably higher than the 95.4% previously reported with SE-HV. The efficacy of YJV-IT was equivalent to 99.0% for NC-HV and 99.6% for SE-HV.</p><p><strong>Conclusion: </strong>Nearly complete protection was achieved with the NC-HV. The efficacy gap between HBV-IT and YJV-IT, which has limited VIT for decades, can be overcome with NC-HV in combination with a high total venom dose rush protocol.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comparison of Chronic Spontaneous Urticaria Clinical Characteristics and Management between Canadian and Israeli Adults.","authors":"Katya Peri, Roy Khalaf, Alona Baum, Aviv Barzilai, Elena Netchiporouk, Michael Nathan Fein, Moshe Ben-Shoshan","doi":"10.1159/000547551","DOIUrl":"10.1159/000547551","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic spontaneous urticaria (CSU) is increasingly recognized as a significant health issue with significant impacts on quality of life in adult populations. Data are sparse regarding differences in clinical characteristics and management of CU in different countries. We aimed to compare adult CU populations in Canada and Israel to identify demographic, clinical, and management differences.</p><p><strong>Methods: </strong>From 2013 to 2024, Canadian adults with CU were prospectively enrolled at allergy clinics, with clinical data including comorbidities, disease severity (UAS7), control (UCT), and treatment collected. Omalizumab was reserved for refractory cases per guidelines. Israeli adults were recruited from 2009 to 2022 at a dermatology clinic, excluding those with inducible CU or unclear diagnoses. Descriptive statistics and multivariable logistic regression were used to compare demographics and treatment patterns across cohorts using R software.</p><p><strong>Results: </strong>From 2013 to 2024, 71 adults at the Montreal General Hospital (MGH) and adjutant clinic were diagnosed with spontaneous urticaria, with a median age of 45.8 years (35.2-59.3) and 22.5% male. Between 2009 and 2022, 151 adults at Sheba Hospital were diagnosed with CSU, with a median age of 48.5 years (32.3-60.0) and 32% male. The male prevalence was significantly higher in Israeli CU patients (p < 0.01). Israeli adults had lower reports of comorbidities, including atopic dermatitis (5.3% vs. 19.7%, p < 0.01) and asthma (7.9% vs. 25.4%, p = 0.04). Antihistamine use was higher in Israel (99.3% vs. 85.9%, p < 0.01), along with glucocorticoids (72.8% vs. 14.1%, p < 0.01).</p><p><strong>Conclusion: </strong>Differences in the demographics, comorbidities, and treatment of CSU may be related to differences between populations and management practices in different countries.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-6"},"PeriodicalIF":1.8,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Ferroptosis in Chronic Inflammatory Diseases of the Upper and Lower Airways.","authors":"Jiaying Li, Jingyun Li, Yunbo Gao, Luo Zhang, Yuan Zhang","doi":"10.1159/000547363","DOIUrl":"10.1159/000547363","url":null,"abstract":"<p><strong>Background: </strong>The pathogenesis of chronic inflammatory diseases in the upper and lower airways is common and mutually influential and should be managed systematically. Disorders of iron metabolism and redox homeostasis imbalance, which lead to the accumulation of reactive oxygen species (ROS) and lipid peroxidation, are considered key common characteristics linking ferroptosis to chronic inflammatory diseases of the upper and lower airways. Recognizing the mechanism of ferroptosis and how it contributes to chronic inflammatory diseases of the upper and lower airways enables a more comprehensive understanding of the pathogenesis of these conditions and offers novel avenues for therapeutic intervention.</p><p><strong>Summary: </strong>Ferroptosis is a novel form of iron-dependent, regulated cell death that is regulated by integrated oxidative and antioxidant systems and is typified by the accumulation of ROS. The Excessive iron can induce the Fenton reaction, leading to the generation of large amounts of ROS. Under the catalytic action of iron-containing enzymes, ROS promotes the formation of lipid hydroperoxides, which is a key mechanism underlying ferroptosis. In contrast, the antioxidant system centered on glutathione peroxidase 4 serves as the primary regulatory pathway for inhibiting ferroptosis. Inflammation promotes the excessive production of ROS and Fe2+ within cells, thereby inducing ferroptosis in airway epithelial cells and inflammatory cells. This, in turn, triggers the release of damage-associated molecular patterns, further amplifying the inflammatory response.</p><p><strong>Key messages: </strong>In this review, we explore the bidirectional interactions between ferroptosis and chronic inflammatory diseases of the upper and lower airways, as well as the potential role and complex effects of ferroptosis in the pathological processes of these diseases.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-13"},"PeriodicalIF":1.8,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unmasking Beta-Lactam Allergies in Children: A Closer Look at Diagnosis and Risk Factors.","authors":"Zeynep Meric, Betul Gemici Karaaslan, Sezin Aydemir, Muhammed Aydin, Dilan Demir Gumus, Sevval Ozyildirim Demirel, Lida Bulbul, Ulviye Mustu, Haluk Cokugras, Mehmet Halil Celiksoy, Esra Yucel, Ayca Kiykim","doi":"10.1159/000547369","DOIUrl":"10.1159/000547369","url":null,"abstract":"<p><strong>Introduction: </strong>Beta-lactam (BL) antibiotics are the most commonly implicated drugs in pediatric drug hypersensitivity reactions. However, most children with suspected BL allergy can safely tolerate these antibiotics after careful evaluation. The aim of this study was to evaluate the clinical characteristics, diagnostic work-up results, and risk factors associated with confirmed BL allergy in children referred with suspected BL hypersensitivity.</p><p><strong>Methods: </strong>We retrospectively analyzed 158 children referred for suspected BL allergy between 2019 and 2025. Clinical and demographic data were collected from medical records. Diagnostic evaluation included skin testing and drug provocation testing. Patients were divided into two groups: those with confirmed BL allergy and those whose allergy label had been removed. Risk factors for BL allergy were compared between groups.</p><p><strong>Results: </strong>The cohort included 158 children (58% male; median age: 100.5 months; interquartile range [IQR]: 75-150.75). The median time from reaction to clinical evaluation was 7 months (IQR: 3-25). The most commonly implicated drug was amoxicillin/clavulanate (81.5%). Immediate reactions (IR) occurred in 47.8% of cases. BL allergy was confirmed in 36.7% of the cases. In the final logistic regression model, the type of hypersensitivity reaction (p = 0.001), severity of reaction (p = 0.001), and the presence of comorbidities (p = 0.008) remained significant predictors of confirmed drug allergy.</p><p><strong>Conclusion: </strong>Given the low true allergy rate, accurate diagnosis and delabeling of suspected BL allergy in children is essential to avoid unnecessary antibiotic restriction.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Real-World Outcomes in Patients with Hereditary Angioedema Receiving Lanadelumab for 3 or More Years.","authors":"William R Lumry, Mark Davis-Lorton, Daniel Soteres, Lucy Earl, Kieran Wynne-Cattanach, Daniel Fox, Krystal Sing, Salomé Juethner, Bob G Schultz","doi":"10.1159/000546987","DOIUrl":"10.1159/000546987","url":null,"abstract":"<p><strong>Introduction: </strong>Hereditary angioedema (HAE) is a rare genetic disorder characterized by unpredictable, painful swelling attacks that significantly impair patients' quality of life (QoL). Clinical trials of lanadelumab led to its approval for long-term prophylaxis in patients with HAE; however, real-world data on long-term lanadelumab use in patients with HAE are limited. This analysis describes real-world outcomes of patients with HAE who have received lanadelumab as long-term prophylaxis for ≥3 years.</p><p><strong>Methods: </strong>From January 2023 to January 2024, investigators collected data from the Adelphi Wave II Disease Specific Programme™, a real-world, cross-sectional survey of physicians and their patients with HAE in the USA. Physicians retrospectively reported attack frequency, attack severity, and QoL before lanadelumab initiation, at 12, 24, and 36 months post initiation, and at the time of the survey.</p><p><strong>Results: </strong>Physicians reported data on 51 patients who had received lanadelumab for ≥3 years. Before lanadelumab initiation, physicians reported attack severity as mild in 49.0% of patients and very severe in 8.2%; at 36 months post lanadelumab initiation, 62.5% of patients experienced mild attacks and none experienced very severe attacks in the preceding year. The proportion of patients experiencing ≥1 attack per month on average decreased from 54.0% before lanadelumab initiation to 9.8% at the time of the survey. The proportion of patients with good or excellent QoL increased from 68.6% before lanadelumab initiation to 88.2% at the time of the survey.</p><p><strong>Conclusion: </strong>In this real-world HAE study, patients treated with lanadelumab for ≥3 years experienced improvements in attack frequency, disease severity, and QoL.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-10"},"PeriodicalIF":1.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Efficacy of Montelukast-Levocetirizine Combination Therapy versus Monotherapy in Allergic Rhinitis: A Systematic Review and Meta-Analysis.","authors":"Ji-Sun Kim, Gulnaz Stybayeva, Se Hwan Hwang","doi":"10.1159/000547410","DOIUrl":"10.1159/000547410","url":null,"abstract":"<p><strong>Introduction: </strong>Combination therapy with antihistamines and leukotriene receptor antagonists (LTRAs) is frequently used in allergic rhinitis (AR), particularly in patients with persistent or inadequately controlled symptoms. However, supporting evidence has been inconsistent. This meta-analysis assessed the efficacy of montelukast combined with levocetirizine in patients with AR by directly comparing the combination therapy with each monotherapy and evaluating individual symptom domains.</p><p><strong>Methods: </strong>A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted, with database searches performed through March 2025. Outcomes included daytime and nighttime total symptom scores, individual nasal symptoms, rhinoconjunctivitis-related quality of life (RQLQ), and treatment-emergent adverse events (TEAEs). Pooled effects were calculated using standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs).</p><p><strong>Results: </strong>Seven RCTs (n = 887) were included. Combination therapy resulted in greater improvement in daytime symptoms (SMD [95% CI]: -0.42 [-0.64 to -0.20]), rhinorrhea (SMD [95% CI]: -0.69 [-1.09 to -0.30]), and nasal congestion (SMD [95% CI]: -0.64 [-1.05 to -0.24]) compared to monotherapy. RQLQ scores improved modestly overall (SMD [95% CI]: -0.37 [-0.72 to -0.01]), but subgroup analyses showed no significant difference compared to individual agents. TEAE rates were similar across groups (OR [95% CI]: 1.05 [0.57 to 1.94]).</p><p><strong>Conclusion: </strong>Montelukast-levocetirizine combination therapy provided superior symptom control without increased adverse events, supporting its use as a potential treatment option in selected patients with AR.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-14"},"PeriodicalIF":1.8,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes of Pollen Allergens in Northern China.","authors":"Wanting Qi, Sainan Bian, Lisha Li, Kai Guan","doi":"10.1159/000547301","DOIUrl":"10.1159/000547301","url":null,"abstract":"<p><strong>Background: </strong>Allergic rhinitis (AR) is a significant global health issue, with pollen allergens being a major cause of seasonal AR and asthma. In northern China, the prevalence of pollen-related allergies is notably higher than in the south due to higher pollen levels. Over the past few decades, climate change and urbanization have considerably transformed pollen profile in northern China.</p><p><strong>Summary: </strong>Northern China experiences two annual pollen peaks: a spring peak (March to May) dominated by tree pollens (e.g., Cupressaceae, Ulmaceae) and a summer/autumn peak (August to September) dominated by weed pollens, particularly from Artemisia, Humulus, and Chenopodiaceae. Climate change has accelerated the onset of flowering periods, increased pollen production, and extended pollen seasons, with extreme weather events and air pollution further exacerbating pollen production and sensitization. Urbanization has increased tree pollens, resulting in spring peak pollen levels gradually exceeding those of summer/autumn in most northern regions. As ecological construction concepts have advanced, the selection of plant species for the shelterbelt and ornamental trees in cities has evolved, leads to changes in the dominant pollens in the north and northeast. Artemisia has been extensively planted in the Northwest for windbreak and sand fixation purposes, resulting in a significant rise in Artemisia pollen levels and sensitization rate with a widespread influence across northern China.</p><p><strong>Key messages: </strong>Pollen allergens in northern China are a major driver of AR and asthma, with two distinct seasonal peaks. Changes in pollen profiles are influenced by natural factors such as geographical location and climate change, as well as social factors, including urbanization, national policies, and urban planning. In northern China, Spring pollen is predominantly composed of tree pollens, significantly influenced by urban planning across different regions. In contrast, summer and autumn pollen is primarily dominated by weed and grass pollens, with weed pollens exhibiting strong allergenic potential and widespread dispersal. The Northwest region is a major potential source for these weed pollens.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-10"},"PeriodicalIF":1.8,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Polycyclic Aromatic Hydrocarbon Metabolites and Psoriasis in US Adults: Evidence from the National Health and Nutrition Examination Survey.","authors":"Jian-Chun Hao, Ruo-Yu Gou, Xing Zhou, Shao-Wei Cheng","doi":"10.1159/000547104","DOIUrl":"10.1159/000547104","url":null,"abstract":"<p><strong>Introduction: </strong>Polycyclic aromatic hydrocarbons (PAHs) are environmental pollutants with widespread human exposure and have been associated with adverse health outcomes. However, their potential relationship with psoriasis remains insufficiently explored. The aim of this study was to investigate the association between PAH exposure and psoriasis.</p><p><strong>Methods: </strong>Data were obtained from the National Health and Nutrition Examination Survey (NHANES) for the periods 2005-2006, 2009-2010, and 2011-2012. Weighted multivariate logistic regression analysis was performed to assess the association between individual PAH metabolites and psoriasis. Bayesian kernel machine regression, quantile g-computation (qgcomp), and weighted quantile sum regression were used to evaluate the relationship between mixed PAH exposure and psoriasis, as well as to determine the relative contributions of specific PAH metabolites. Stratified and sensitivity analyses were conducted to assess result stability.</p><p><strong>Results: </strong>A total of 4,912 participants (mean age, 43.52 years; 95% confidence interval, 42.65-44.39 years) were included, of whom 2,514 (51.18%) were female, and 141 (2.87%) were diagnosed with psoriasis. Multivariate logistic regression analysis identified significant positive associations between psoriasis and seven urinary PAH metabolites: 2-hydroxynaphthalene, 3-hydroxyfluorene, 2-hydroxyfluorene, 3-hydroxyphenanthrene, 1-hydroxyphenanthrene, 2-hydroxyphenanthrene, and 1-hydroxypyrene. Analysis of mixed exposure PAH across all three models demonstrated significant positive associations between urinary PAH metabolites and psoriasis, with 2-hydroxyphenanthrene and 2-hydroxynaphthalene identified as primary contributors. Stratified and sensitivity analyses confirmed the robustness of these results, and the observed associations persisted among nonsmokers.</p><p><strong>Conclusion: </strong>Both single and mixed exposure analyses demonstrated a positive association between PAH exposure and psoriasis. These findings suggest that reducing PAH exposure may help mitigate psoriasis risk.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-16"},"PeriodicalIF":1.8,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}